A Study on Vasambu Kuligai(Internal) for the treatment of NEER MANDHAM (URINARY TRACT INFECTION) in children

Preclinical and clinical evaluation of Vasambu Kuligai in the management of Neer mandham (urinary tract infection) in paediatric age group - Nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/02/103613

Enrollment

Registered

2026-02-11

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N390- Urinary tract infection, site notspecified

Interventions

Intervention1: Vasambu Kuligai: Vasambu Kuligai 1 tablet (56 mg) twice daily with warm water for 14 days Route: Oral administration Intervention2: Vasambu Kuligai: Vasambu Kuligai 1 tablet (56 mg)

Eligibility

Inclusion criteria

Inclusion criteria: (1)Children age 3 12 yrs, (2)dysuria, nausea, vomitting (3)burning urination, (4)Abdominal pain (5)fever with chills

Exclusion criteria

Exclusion criteria: (1)haematuria, (2)pyelonephritis, (3)chronic cystitis, (4)chronic urethritis, (5)urinary tract malfunction.

Design outcomes

Primary

Measure	Time frame
The study is expected to demonstrate the therapeutic efficacy and safety of Vasambu Kuligai in the management of Neer Mantham (UTI) in children. The findings may support its integration into Siddha-based paediatric care and provide evidence for its pharmacological actions.Timepoint: The study outcomes related to therapeutic efficacy and safety will be assessed at predefined time points, namely at baseline (Day 0), during treatment (Day 7), and at the end of treatment (Day 14), to evaluate the effects of Vasambu Kuligai in the management of Neer Mantham (urinary tract infection) in children and to support its integration into Siddha-based paediatric care.	—

Measure

Time frame

The study is expected to demonstrate the therapeutic efficacy and safety of Vasambu Kuligai in the management of Neer Mantham (UTI) in children. The findings may support its integration into Siddha-based paediatric care and provide evidence for its pharmacological actions.Timepoint: The study outcomes related to therapeutic efficacy and safety will be assessed at predefined time points, namely at baseline (Day 0), during treatment (Day 7), and at the end of treatment (Day 14), to evaluate the effects of Vasambu Kuligai in the management of Neer Mantham (urinary tract infection) in children and to support its integration into Siddha-based paediatric care.

—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr A ANBUMALAR MD S

GOVERNMENT SIDDHA MEDICAL COLLEGE

anbumalara@gmail.com9788232433

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026